|Denaro||73,95 x 1300|
|Lettera||74,00 x 1400|
|Min-Max giorno||73,01 - 75,39|
|Intervallo di 52 settimane||12,47 - 95,21|
|Beta (5 anni mensile)||N/D|
|Rapporto PE (ttm)||N/D|
|Prossima data utili||04 nov 2020 - 09 nov 2020|
|Rendimento e dividendo (forward)||N/D (N/D)|
|Data ex dividendo||N/D|
|Stima target 1A||94,15|
Moderna Inc said that the U.S. government’s Biomedical Advanced Research and Development Authority (BARDA) has committed an additional $472 million in funding to support scaling up of manufacturing and clinical development of its novel coronavirus vaccine.
Moderna rallied strongly overnight after a Phase 1 drug trial showed promising results in the battle against COVID-19.
S&P; 500 futures are up in premarket trading as traders bet that the world will have a vaccine for COVID-19 this year.